BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 33040674)

  • 21. Significance of inflammatory indexes in atezolizumab monotherapy outcomes in previously treated non-small-cell lung cancer patients.
    Katayama Y; Yamada T; Chihara Y; Tanaka S; Tanimura K; Okura N; Hirose K; Uda S; Shiotsu S; Hirai S; Hiranuma O; Harada T; Shimamoto T; Iwasaku M; Kaneko Y; Uchino J; Takeda T; Takayama K
    Sci Rep; 2020 Oct; 10(1):17495. PubMed ID: 33060826
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic value of morphological characteristics assessed by CT scan in patients with non-small cell lung cancer treated with nivolumab.
    Minemura H; Moriya H; Imai H; Sugiyama T; Yamada Y; Higuchi M; Kaira K; Ozaki Y; Kanazawa K; Yokouchi H; Kasai T; Kaburagi T; Suzuki H; Minato K; Shibata Y
    Thorac Cancer; 2020 Dec; 11(12):3521-3527. PubMed ID: 33044045
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chronic Kidney Disease and Cancer: Inter-Relationships and Mechanisms.
    Hu M; Wang Q; Liu B; Ma Q; Zhang T; Huang T; Lv Z; Wang R
    Front Cell Dev Biol; 2022; 10():868715. PubMed ID: 35663394
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Successful Treatment of Non-small-cell Lung Cancer with Atezolizumab Following Tubulointerstitial Nephritis Due to Pembrolizumab.
    Taki T; Oda N; Fujioka Y; Mitani R; Tokura T; Takata I; Oshiro Y; Takigawa N
    Intern Med; 2020 Jul; 59(13):1639-1642. PubMed ID: 32269191
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Renal Effects after Pembrolizumab Treatment for Non-small Cell Lung Carcinoma.
    Oki R; Hirakawa Y; Kimura H; Honda K; Hinata M; Abe H; Domoto Y; Tanaka G; Nagase T; Nangaku M
    Intern Med; 2020 Apr; 59(7):977-981. PubMed ID: 31813918
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acute Tubulointerstitial Nephritis: A Case Report on Rare Adverse Effect of Pembrolizumab.
    Basnet S; Dhital R; Tharu B
    Medicina (Kaunas); 2019 May; 55(5):. PubMed ID: 31117208
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of Acute Interstitial Nephritis With Programmed Cell Death 1 Inhibitor Therapy in Lung Cancer Patients.
    Shirali AC; Perazella MA; Gettinger S
    Am J Kidney Dis; 2016 Aug; 68(2):287-291. PubMed ID: 27113507
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pembrolizumab-induced hypothyroidism caused reversible increased serum creatinine levels: a case report.
    Matsuoka N; Tsuji K; Ichihara E; Hara T; Fukushima K; Toma K; Kitamura S; Inagaki K; Sugiyama H; Wada J
    BMC Nephrol; 2020 Mar; 21(1):113. PubMed ID: 32234009
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interstitial nephritis with pembrolizumab: A case report and review.
    Peláez Bejarano A; Montero Pérez O; Inoriza Rueda A; Garrido Martínez MT
    J Oncol Pharm Pract; 2021 Jun; 27(4):1046-1051. PubMed ID: 33040674
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bullous pemphigoid in elderly woman affected by non-small cell lung cancer treated with pembrolizumab: A case report and review of literature.
    Cosimati A; Rossi L; Didona D; Forcella C; Didona B
    J Oncol Pharm Pract; 2021 Apr; 27(3):727-733. PubMed ID: 32772795
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The safety and efficacy of pembrolizumab for the treatment of non-small cell lung cancer.
    Mazarico Gallego JM; Herrera Juárez M; Paz-Ares L
    Expert Opin Drug Saf; 2020 Mar; 19(3):233-242. PubMed ID: 32129104
    [No Abstract]   [Full Text] [Related]  

  • 32. Severe Thrombocytopenia Associated With Pembrolizumab in Patients With Non-small Cell Lung Cancer (NSCLC): A Case Report and Literature Review.
    Mouri A; Kaira K; Shiono A; Miura YU; Kagamu H
    In Vivo; 2020; 34(2):877-880. PubMed ID: 32111798
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pericardial effusion due to pembrolizumab-induced immunotoxicity: A case report and literature review.
    Atallah-Yunes SA; Kadado AJ; Soe MH
    Curr Probl Cancer; 2019 Oct; 43(5):504-510. PubMed ID: 30685067
    [TBL] [Abstract][Full Text] [Related]  

  • 34.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 35.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 36.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.